推进T细胞功能的体内检测:人源OX40 PET示踪剂89Zr-伊伏洛单抗的研发与临床前评价
本研究基于临床评价过的治疗性抗体伊伏洛单抗,研发了人源OX40特异性PET示踪剂89Zr-伊伏洛单抗,并在体外、荷瘤小鼠及急性移植物抗宿主病转基因小鼠模型中验证其特异性。结果显示该示踪剂可检测活化T细胞及体内T细胞激活,作者认为其有临床转化前景,并指出需进一步研究其监测和预测免疫治疗反应的能力。
要点
- 89Zr-伊伏洛单抗在体外对活化人T细胞的结合较静息细胞显著增高(P < 0.0001)。
- 荷瘤小鼠连续5天PET/CT显示huOX40+ HEK293肿瘤摄取较HEK293肿瘤显著增高(P < 0.0001)。
- 在急性移植物抗宿主病小鼠中,该示踪剂可检测脾、肠系膜淋巴结和胃肠道的T细胞激活。
核心结论
- 89Zr-伊伏洛单抗是一种有前景的放射性示踪剂,可作为活化T细胞的显像剂用于临床转化。
- 作者认为需进一步研究其监测和预测不同癌症免疫治疗模式反应的能力。
研究设计与样本
- 临床前研究:优化去铁胺偶联与89Zr放射性标记伊伏洛单抗,制备89Zr-伊伏洛单抗。
- 体外使用原代人T细胞和稳定转染人OX40(huOX40+)的人胚胎肾293(HEK293)细胞评估特异性。
- 体内使用皮下植入huOX40+ HEK293或亲本HEK293肿瘤的荷瘤小鼠确认特异性与生物分布。
- 采用表达人OX40的转基因小鼠T细胞诱导的急性移植物抗宿主病模型评估体内T细胞激活检测。
- 通过离体伽马计数、放射自显影和免疫组织化学验证示踪剂结合特异性。
主要发现
- 89Zr-伊伏洛单抗可重复合成,体外对活化人T细胞的结合较静息细胞显著增高(P < 0.0001)。
- 体外对huOX40+ HEK293细胞的结合较HEK293细胞显著增高(P < 0.0001)。
- 荷瘤小鼠连续5天纵向PET/CT显示huOX40+ HEK293肿瘤的示踪剂蓄积显著高于HEK293肿瘤(P < 0.0001)。
- 在表达人OX40的转基因小鼠T细胞诱导的移植物抗宿主病小鼠中,89Zr-伊伏洛单抗成功检测到脾、肠系膜淋巴结和胃肠道的T细胞激活,与对照组相比(全身照射组P < 0.0001;骨髓组P < 0.001)。
- 离体伽马计数、放射自显影和免疫组织化学证实了PET发现并确认了示踪剂对OX40的特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需进一步研究该示踪剂监测和预测不同癌症免疫治疗模式反应的能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The variable response to cancer immunotherapies highlights a critical gap in our ability to predict and monitor treatment efficacy. To address this, there is an urgent clinical need for advanced molecular imaging technologies that can noninvasively and precisely assess whole-body immune responses. The OX40 receptor (CD134), a potent costimulatory molecule on T cells, serves as a highly specific marker of T-cell activation, an early and crucial event in immunotherapy efficacy. In this study, we report the development of a human OX40-specific radiotracer based on a clinically evaluated therapeutic-ivuxolimab-and assess its utility for PET imaging of activated T cells in vivo. Methods: Deferoxamine conjugation and 89Zr radiolabeling were optimized for ivuxolimab. In vitro specificity of the resultant tracer, 89Zr-ivuxolimab, was then assessed using primary human T cells and stably transfected human OX40+ (huOX40+) human embryonic kidney 293 (HEK293) cells. In vivo specificity and biodistribution of 89Zr-ivuxolimab were confirmed in subcutaneously implanted huOX40+ HEK293 or parental HEK293 tumor-bearing mice. To evaluate 89Zr-ivuxolimab's utility for detecting T-cell activation in vivo, we used a transgenic human OX40 murine model of acute graft-versus-host disease. Ex vivo gamma counting, autoradiography, and immunohistochemistry were performed to verify tracer-binding specificity. Results: 89Zr-ivuxolimab was reproducibly synthesized and showed significantly increased in vitro binding to activated human T cells versus resting cells (P < 0.0001) and increased binding to huOX40+ HEK293 cells versus HEK293 cells (P < 0.0001). Longitudinal PET/CT imaging of tumor-bearing mice over 5 d revealed markedly higher tracer accumulation in huOX40+ HEK293 tumors compared with HEK293 tumors (P < 0.0001). 89Zr-ivuxolimab successfully detected T-cell activation in the spleen, mesenteric lymph node, and gastrointestinal tract of mice with graft-versus-host disease induced by transgenic murine T cells expressing human OX40, compared with control groups (total body irradiation, P < 0.0001; bone marrow, P < 0.001). Ex vivo gamma counting of tissues, autoradiography, and immunohistochemistry corroborated PET findings and confirmed tracer specificity for OX40. Conclusion: 89Zr-ivuxolimab is a promising radiotracer for clinical translation as an imaging agent for activated T cells. Further investigation of its ability to monitor and predict response to different cancer immunotherapy modalities is warranted.
引用
- Kalita M, Kuo RC, Reyes ST, et al. Advancing In Vivo Detection of T-Cell Function: Development and Preclinical Evaluation of 89Zr-Ivuxolimab, a Human OX40 PET Tracer. J Nucl Med. 2025. PMID: 40707142. doi:10.2967/jnumed.125.269799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。